Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 2
1953 1
1954 2
1955 2
1956 2
1957 3
1959 1
1960 1
1961 2
1962 5
1963 2
1964 1
1965 2
1967 2
1968 5
1969 6
1970 8
1971 10
1972 5
1973 8
1974 6
1975 4
1976 6
1977 14
1978 11
1979 7
1980 9
1981 8
1982 4
1983 7
1984 20
1985 16
1986 16
1987 15
1988 25
1989 26
1990 29
1991 18
1992 24
1993 32
1994 22
1995 28
1996 23
1997 37
1998 33
1999 38
2000 41
2001 35
2002 42
2003 33
2004 28
2005 34
2006 34
2007 53
2008 62
2009 55
2010 58
2011 71
2012 67
2013 77
2014 66
2015 66
2016 78
2017 87
2018 85
2019 93
2020 116
2021 144
2022 122
2023 95
2024 115
2025 106
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,206 results

Results by year

Filters applied: . Clear all
Page 1
Soft-tissue sarcoma in adolescents and young adults.
Kunisada T, Nakata E, Fujiwara T, Hosono A, Takihira S, Kondo H, Ozaki T. Kunisada T, et al. Among authors: ozaki t. Int J Clin Oncol. 2023 Jan;28(1):1-11. doi: 10.1007/s10147-022-02119-7. Epub 2022 Jan 27. Int J Clin Oncol. 2023. PMID: 35084598 Review.
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
Tanaka K, Sugisaka J, Shiraishi Y, Watanabe Y, Daga H, Azuma K, Nishino K, Mori M, Ota T, Saito H, Hata A, Sakaguchi T, Kozuki T, Akamatsu H, Matsumoto H, Tachihara M, Wakuda K, Sato Y, Ozaki T, Tsuchiya-Kawano Y, Yamamoto N, Nakagawa K, Okamoto I. Tanaka K, et al. Among authors: ozaki t. Nat Commun. 2025 Mar 22;16(1):2825. doi: 10.1038/s41467-025-58186-7. Nat Commun. 2025. PMID: 40121197 Free PMC article. Clinical Trial.
Immunotherapy for sarcomas.
Nakata E, Fujiwara T, Kunisada T, Ito T, Takihira S, Ozaki T. Nakata E, et al. Among authors: ozaki t. Jpn J Clin Oncol. 2021 Apr 1;51(4):523-537. doi: 10.1093/jjco/hyab005. Jpn J Clin Oncol. 2021. PMID: 33611603 Review.
Quest for Science, Spirit, and Skills.
Ozaki T. Ozaki T. J Orthop Sci. 2023 Mar;28(2):299-301. doi: 10.1016/j.jos.2022.11.001. Epub 2023 Jan 13. J Orthop Sci. 2023. PMID: 36642582 Free article.
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, Rajasekhar VK, Yoshida A, Kondo H, Hata T, Tazawa H, Dogan Y, Moore MAS, Fujiwara T, Ozaki T, Purdue E, Healey JH. Fujiwara T, et al. Among authors: ozaki t. Mol Cancer Ther. 2021 Aug;20(8):1388-1399. doi: 10.1158/1535-7163.MCT-20-0591. Epub 2021 Jun 4. Mol Cancer Ther. 2021. PMID: 34088832 Free PMC article.
A BN-Benzvalene.
Ozaki T, Bentley SK, Rybansky N, Li B, Liu SY. Ozaki T, et al. J Am Chem Soc. 2024 Sep 11;146(36):24748-24753. doi: 10.1021/jacs.4c08088. Epub 2024 Jul 31. J Am Chem Soc. 2024. PMID: 39082667 Free PMC article.
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T, Osaki A, Yanagita Y, Nakamura S, Nakamura R, Sambe T, Ozaki T, Schiavon G, Howell SJ, Toi M. Tokunaga E, et al. Among authors: ozaki t. Breast Cancer. 2025 Jan;32(1):132-143. doi: 10.1007/s12282-024-01640-z. Epub 2024 Oct 8. Breast Cancer. 2025. PMID: 39379782 Free PMC article. Clinical Trial.
Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting.
Yamagami H, Ozaki T, Ogasawara K, Nagata I, Matsumaru Y, Yoshimura S, Sasaki M, Nagatsuka K, Minematsu K, Nagai Y, Sakai C, Matsumoto Y, Ezura M, Ishihara H, Sakai N; CAS-CARE Investigators. Yamagami H, et al. Among authors: ozaki t. Stroke. 2024 Dec;55(12):2776-2785. doi: 10.1161/STROKEAHA.124.047210. Epub 2024 Nov 25. Stroke. 2024. PMID: 39585936 Free article. Clinical Trial.
2,206 results